FILTER
FILTERED INTERVIEW RESULTS
James Sapirstein
CHAIRMAN, PRESIDENT, AND CEO, FIRST WAVE BIOPHARMA
“We are happy to report that we have initiated the Phase 2 SPAN adrulipase clinical and are currently screening patients for the study. We anticipate topline data by mid-2023.”
Kendalle O’Connell
CEO AND PRESIDENT, MASSBIO
"In 2022, Massachusetts received 25% of all biopharma VC funding in the US. We are seeing new clusters emerge outside the traditional hubs of Kendall Square and Boston."
Arda Ural
AMERICAS INDUSTRY MARKET LEADER, HEALTH SCIENCES & WELLNESS, EY USA
"We are going to help the industry digitalize, prepare for the innovation deficit due to expiring patents and improve strategies that lead to better M&A opportunities."
Eric J. Mears
VICE PRESIDENT, HALEY & ALDRICH
"Arizona currently uses as much water now as it did in the mid 1950’s. Conservation, water banking, and forward-looking water laws have played a tremendous role in this."
Darryl Sockwell & Michael Judd
WEST COAST DIVISION DISTRICT MANAGER (DS) & WEST COAST DIVISION BUSINESS DEVELOPMENT MANAGER (MJ), MMR CONSTRUCTORS
“We have tremendous growth opportunities, particularly in the western region where many of the larger mines are located. The schedule and demand in the mining sector is aggressive and I don’t see it slowing down anytime soon.”
David Schaffer
EXECUTIVE DIRECTOR, QB3
"The Bay Area offers a confluence of universities, investors and companies, and we are interested in strengthening bridges between these institutions to streamline the process of technology translation."
Mark A. Goldberg
CEO, ALLUCENT
"Given that a significant amount of intellectual property and cutting-edge science resides within smaller companies, we created a purpose-built firm to help smaller players develop their products and bring them to market."
Gil Roth
PRESIDENT, PBOA
"The Ukraine crisis highlighted how Europe needs to look at its energy supply and how it will make sure they have secure supply chains. Part of that has involved the US more closely. Geopolitics will have a more significant impact going forward."
Terry Myerson
CEO, TRUVETA
"Truveta Studio is the first data and analytics solution to study patient care and outcomes for all conditions, drugs, and medical devices. Pfizer is using Truveta Studio to study COVID-19."
Liping Liu
FOUNDER & CEO, HIGHTIDE THERAPEUTICS
"As more robust drug candidates are emerging, I am willing to bet that we will have the first NASH drug approved in 2023."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Latam North and Caribbean Mining 2025
The Latam North and Caribbean Mining 2025 report adopts a regional formula to promote cross-border investment. Each country is given room to shine individually, while also being woven into broader narratives.
The Latam North and Caribbean Mining 2025 report adopts a regional formula to promote cross-border investment. Each country is given room to shine individually, while also being woven into broader narratives.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
